Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer


Evaluation of Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Track 1: Selection of durvalumab as consolidation therapy for locally advanced squamous cell lung cancer
Track 2: Effect of PD-L1 expression on the choice of durvalumab as consolidation therapy
Track 3: Use of durvalumab for patients with locally advanced NSCLC and targetable alterations
Track 4: Timing of initiation of durvalumab therapy

Integration of Immune Checkpoint Inhibitors Into the Management of Locally Advanced NSCLC

Track 5: Reduction in the risk of disease progression with durvalumab for Stage III NSCLC
Track 6: Consolidation durvalumab in elderly patients with locally advanced lung adenocarcinoma; role of durvalumab after surgical excision and chemoradiation therapy

Recognition and Management of Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced NSCLC

Track 7: Management of dyspnea after the initiation of consolidation durvalumab
Track 8: Approach to the treatment of diarrhea associated with durvalumab
Track 9: Safety of durvalumab in patients with locally advanced NSCLC and a history of autoimmune disease
Track 10: Effect of radiation dose on outcomes in the Phase III PACIFIC trial
Track 11: Diagnosis and treatment of radiation pneumonitis versus pneumonitis associated with immune checkpoint inhibitors

Novel Approaches Under Investigation with Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC

Track 12: Therapeutic approach for a patient who presents with locally advanced NSCLC and oligometastases to the bones
Track 13: Clinical care of a patient with nonmetastatic NSCLC who experiences disease progression soon after completion of durvalumab therapy
Track 14: Effect of the dose of radiation on the abscopal effect
Track 15: Perspective on the use of immunotherapy for a patient with Stage IIIB NSCLC that is too large for up-front radiation therapy
Track 16: Sequencing therapy for a patient with Stage IIIA squamous cell lung cancer
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Shruti Jolly, MD
Department of Radiation Oncology
Chief of Brachytherapy Services
Associate Chair of Community Practices
Associate Medical Director
UMHS Strategic Planning and Business Development
University of Michigan
Ann Arbor, Michigan
Billy Wiseman Loo Jr, MD, PhD
Professor, Thoracic Radiation Oncology
Program Leader
Department of Radiation Oncology
Stanford University School of Medicine
Stanford, California
Jyoti D Patel, MD
Professor of Medicine
Director, Thoracic Oncology
The University of Chicago
Chicago, Illinois